|Mr. David Ian Johnson||Pres, CEO & Director||N/A||N/A||1958|
|Mr. Joseph M. Warusz||CFO, Treasurer & Sec.||N/A||N/A||1956|
|Dr. Phillip D. Forman M.D., DPM||Exec. VP of Clinical Affairs||N/A||N/A||1959|
|Mr. Gregory Robb||VP of Operations||N/A||N/A||N/A|
Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania.
Alliqua BioMedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.